[HTML][HTML] Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter …
X Jiang, P Wang, K Su, H Li, H Chi, F Wang, Y Liu… - Annals of …, 2025 - Elsevier
Abstract Introduction and Objectives We initiated this study to explore the efficacy of
camrelizumab combined with transcatheter arterial chemoembolization (TACE) plus …
camrelizumab combined with transcatheter arterial chemoembolization (TACE) plus …
Commentary: Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma (HCC) in people living with HIV: a report of two cases
C Sun, Y Wen, J Zhou - Frontiers in Oncology, 2024 - frontiersin.org
Although higher HCC incidence risk was reported among people living with HIV (PLWH)
compared to general population, it actually declined from 2001 to 2019 (1), especially …
compared to general population, it actually declined from 2001 to 2019 (1), especially …